Literature DB >> 20463105

Correlates of protection induced by vaccination.

Stanley A Plotkin1.   

Abstract

This paper attempts to summarize current knowledge about immune responses to vaccines that correlate with protection. Although the immune system is redundant, almost all current vaccines work through antibodies in serum or on mucosa that block infection or bacteremia/viremia and thus provide a correlate of protection. The functional characteristics of antibodies, as well as quantity, are important. Antibody may be highly correlated with protection or synergistic with other functions. Immune memory is a critical correlate: effector memory for short-incubation diseases and central memory for long-incubation diseases. Cellular immunity acts to kill or suppress intracellular pathogens and may also synergize with antibody. For some vaccines, we have no true correlates, but only useful surrogates, for an unknown protective response.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20463105      PMCID: PMC2897268          DOI: 10.1128/CVI.00131-10

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  196 in total

Review 1.  Difficulties in establishing a serological correlate of protection after immunization with Haemophilus influenzae conjugate vaccines.

Authors:  H Käyhty
Journal:  Biologicals       Date:  1994-12       Impact factor: 1.856

2.  Polysaccharide vaccines of group A Neisseria meningtitidis and Haemophilus influenzae type b: a field trial in Finland.

Authors:  P H Mäkelä; H Peltola; H Käyhty; H Jousimies; O Pettay; E Ruoslahti; A Sivonen; O V Renkonen
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

3.  Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine.

Authors:  R B Belshe; W C Gruber; P M Mendelman; H B Mehta; K Mahmood; K Reisinger; J Treanor; K Zangwill; F G Hayden; D I Bernstein; K Kotloff; J King; P A Piedra; S L Block; L Yan; M Wolff
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

4.  Francisella tularensis infection-derived monoclonal antibodies provide detection, protection, and therapy.

Authors:  Anne G Savitt; Patricio Mena-Taboada; Gloria Monsalve; Jorge L Benach
Journal:  Clin Vaccine Immunol       Date:  2009-01-28

5.  Immunogenicity of a reduced schedule of pneumococcal conjugate vaccine in healthy infants and correlates of protection for serotype 6B in the United Kingdom.

Authors:  David Goldblatt; Jo Southern; Lindsey Ashton; Nick Andrews; Sarah Woodgate; Polly Burbidge; Pauline Waight; Elizabeth Miller
Journal:  Pediatr Infect Dis J       Date:  2010-05       Impact factor: 2.129

6.  Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification.

Authors:  Scott J Balsitis; Katherine L Williams; Ruben Lachica; Diana Flores; Jennifer L Kyle; Erin Mehlhop; Syd Johnson; Michael S Diamond; P Robert Beatty; Eva Harris
Journal:  PLoS Pathog       Date:  2010-02-12       Impact factor: 6.823

7.  Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.

Authors:  H Peltola; H Mäkelä; H Käyhty; H Jousimies; E Herva; K Hällström; A Sivonen; O V Renkonen; O Pettay; V Karanko; P Ahvonen; S Sarna
Journal:  N Engl J Med       Date:  1977-09-29       Impact factor: 91.245

8.  Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies.

Authors:  George R Siber; Ih Chang; Sherryl Baker; Philip Fernsten; Katherine L O'Brien; Mathuram Santosham; Keith P Klugman; Shabir A Madhi; Peter Paradiso; Robert Kohberger
Journal:  Vaccine       Date:  2007-02-21       Impact factor: 3.641

9.  Sindbis virus-based measles DNA vaccines protect cotton rats against respiratory measles: relevance of antibodies, mucosal and systemic antibody-secreting cells, memory B cells, and Th1-type cytokines as correlates of immunity.

Authors:  Marcela F Pasetti; Karina Ramirez; Aldo Resendiz-Albor; Jeffrey Ulmer; Eileen M Barry; Myron M Levine
Journal:  J Virol       Date:  2009-01-07       Impact factor: 5.103

10.  Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles.

Authors:  Denise Nardelli-Haefliger; Daniel Wirthner; John T Schiller; Douglas R Lowy; Allan Hildesheim; Françoise Ponci; Pierre De Grandi
Journal:  J Natl Cancer Inst       Date:  2003-08-06       Impact factor: 13.506

View more
  592 in total

1.  Commentary on "Principal stratification - a goal or a tool?" by Judea Pearl.

Authors:  Peter B Gilbert; Michael G Hudgens; Julian Wolfson
Journal:  Int J Biostat       Date:  2011-09-20       Impact factor: 0.968

2.  Nomenclature for immune correlates of protection after vaccination.

Authors:  Stanley A Plotkin; Peter B Gilbert
Journal:  Clin Infect Dis       Date:  2012-03-20       Impact factor: 9.079

Review 3.  The development of vaccines: how the past led to the future.

Authors:  Stanley A Plotkin; Susan L Plotkin
Journal:  Nat Rev Microbiol       Date:  2011-10-03       Impact factor: 60.633

4.  Moving ahead an HIV vaccine: to neutralize or not, a key HIV vaccine question.

Authors:  Thomas J Hope
Journal:  Nat Med       Date:  2011-10-11       Impact factor: 53.440

5.  Moving ahead an HIV vaccine: use both arms to beat HIV.

Authors:  Bruce D Walker; Rafi Ahmed; Stanley Plotkin
Journal:  Nat Med       Date:  2011-10-11       Impact factor: 53.440

Review 6.  Contributions of humoral and cellular immunity to vaccine-induced protection in humans.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Virology       Date:  2011-01-08       Impact factor: 3.616

7.  Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses.

Authors:  Paul V Licciardi; Anne Balloch; Fiona M Russell; Robert L Burton; Jisheng Lin; Moon H Nahm; Edward K Mulholland; Mimi L K Tang
Journal:  J Allergy Clin Immunol       Date:  2012-02-02       Impact factor: 10.793

8.  JE-ADVAX vaccine protection against Japanese encephalitis virus mediated by memory B cells in the absence of CD8(+) T cells and pre-exposure neutralizing antibody.

Authors:  Maximilian Larena; Natalie A Prow; Roy A Hall; Nikolai Petrovsky; Mario Lobigs
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

Review 9.  Modeling HIV vaccine trials of the future.

Authors:  Peter B Gilbert; Ying Huang; Holly E Janes
Journal:  Curr Opin HIV AIDS       Date:  2016-11       Impact factor: 4.283

10.  NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults.

Authors:  Clint S Schmidt; C Jo White; Ashraf S Ibrahim; Scott G Filler; Yue Fu; Michael R Yeaman; John E Edwards; John P Hennessey
Journal:  Vaccine       Date:  2012-10-22       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.